sodium-glucose-cotransporter

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 41/100

   Risk of depression and dementia among individuals treated with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists

   ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Current opinion in psychiatry · 2025-02-19 · Drug development

   The effects of these medicines on mood have not been as well explored, but there are concerns about the potential increased risk of suicidality among GLP-1 RA users.

   • Risk Factors
2. 71/100

   Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks

   ✓ Peer-reviewed alzhub usefulness score 71 out of 100. Diabetes, obesity & metabolism · 2024-09-09 · Drug development

   The use of SGLT-2 inhibitor was associated with a lower risk of incident dementia and all-cause mortality in older adults with T2D compared to DPP-4 inhibitor and GLP-1 RA.

   • Risk Factors
   • Treatments
3. 60/100

   Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer's disease: A population-based study

   ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Pharmacological research · 2024-07-04 · Drug development

   The lack of effective treatments for dementia has led to explore the potential of antidiabetic agents as a possible approach.

   • Treatments
4. 52/100

   The Effect of the Sodium-Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer's Disease

   ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Biomedicines · 2023-03-27 · Drug development

   Type 2 diabetes mellitus increases the risk of sporadic Alzheimer's disease (sAD), and antidiabetic drugs, including the sodium-glucose cotransporter inhibitors (SGLTI), are being studied as possible sAD therapy.

   • Treatments
5. 79/100

   Association of Sodium-Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study

   ✓ Peer-reviewed alzhub usefulness score 79 out of 100. Diabetes care · 2023-02-01 · Drug development

   SGLT2 inhibitors showed an association with lower dementia risk in older people with T2D. Randomized controlled trials are warranted.

   • Risk Factors
6. 74/100

   Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis

   ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Frontiers in cardiovascular medicine · 2021-10-21 · Drug development

   A total of 13,276 SGLT2I and 36,544 DPP4I users (total n = 51,460; median age: 66.3 years old [interquartile range (IQR): 58-76], 55.65% men) were studied (follow-up: 472 [120-792] days).

   • Treatments

All topic tags with their study counts